Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes.
作者信息
Saeed Zeb I, Akturk Halis K, Aleppo Grazia, Kruger Davida, Levy Carol J, Mader Julia K, Sherr Jennifer L, Shah Viral N
机构信息
Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA.
Division of Endocrinology, Diabetes and Metabolism, Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO.
出版信息
Clin Diabetes. 2024 Sep 20;43(1):131-138. doi: 10.2337/cd24-0067. eCollection 2025 Winter.
Abstract
摘要
相似文献
1
Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes.1型糖尿病成人患者使用胰高血糖素样肽1受体激动剂治疗时的胰岛素滴定建议
Clin Diabetes. 2024 Sep 20;43(1):131-138. doi: 10.2337/cd24-0067. eCollection 2025 Winter.
2
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
3
Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂替尔泊肽对2型糖尿病患者心率的影响：一项系统评价及成对和网状荟萃分析
Diabetes Obes Metab. 2024 Feb;26(2):548-556. doi: 10.1111/dom.15342. Epub 2023 Oct 20.
4
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
5
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.胰岛素和胰高血糖素样肽 1 受体激动剂联合治疗 2 型糖尿病：随机对照试验的系统评价和荟萃分析。
Diabetes Care. 2017 Apr;40(4):614-624. doi: 10.2337/dc16-1957.
6
Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.2型糖尿病患者中使用钠-葡萄糖协同转运蛋白2抑制剂、二肽基肽酶4抑制剂或胰高血糖素样肽1激动剂后新发外周动脉疾病的比较：一项基于人群的队列研究。
J Am Heart Assoc. 2025 Jun 3;14(11):e034175. doi: 10.1161/JAHA.123.034175. Epub 2025 May 22.
7
Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂与基础胰岛素的固定比例组合：一项系统评价和荟萃分析。
Endocrine. 2017 Jun;56(3):485-494. doi: 10.1007/s12020-017-1293-6. Epub 2017 Apr 12.
8
Impact of real-time glucose monitoring using FreeStyle Libre 3 on glycaemia in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial protocol.使用FreeStyle Libre 3进行实时血糖监测对基础胰岛素联合SGLT2抑制剂和/或GLP-1激动剂治疗的2型糖尿病患者血糖水平的影响：FreeDM2随机对照试验方案
BMJ Open. 2025 Apr 15;15(4):e090154. doi: 10.1136/bmjopen-2024-090154.
9
Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂的使用与围手术期肺误吸之间的关联：一项系统评价和荟萃分析。
Anaesthesia. 2025 Jul;80(7):846-858. doi: 10.1111/anae.16601. Epub 2025 Apr 15.
10
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.胰高血糖素样肽-1受体激动剂在2型糖尿病治疗中的疗效与安全性：一项系统评价和混合治疗比较分析
Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17.
引用本文的文献
1
Registration and Real-Life Studies on Automated Insulin Delivery Systems.自动胰岛素输注系统的注册及真实世界研究
J Diabetes Sci Technol. 2025 Jul;19(4):924-936. doi: 10.1177/19322968251334993. Epub 2025 Jul 1.
本文引用的文献
1
Tirzepatide-Induced Rapid Weight Loss-Related Thyrotoxicosis.替尔泊肽诱导的与快速体重减轻相关的甲状腺毒症。
JAMA Intern Med. 2024 Oct 1;184(10):1246-1247. doi: 10.1001/jamainternmed.2024.2919.
2
Hyperglycemic Crises in Adults With Diabetes: A Consensus Report.成人糖尿病高血糖危象：共识报告。
Diabetes Care. 2024 Aug 1;47(8):1257-1275. doi: 10.2337/dci24-0032.
3
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?肠降血糖素类似物与急性胰腺炎：敌是友非？
Curr Opin Gastroenterol. 2024 Sep 1;40(5):404-412. doi: 10.1097/MOG.0000000000001057. Epub 2024 Jul 4.
4
Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ.在使用串联Control-IQ的1型糖尿病成人患者中，替尔泊肽作为辅助治疗时基础胰岛素和大剂量胰岛素需求量的变化。
Diabetes Ther. 2024 Jul;15(7):1647-1655. doi: 10.1007/s13300-024-01592-9. Epub 2024 May 14.
5
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.替尔泊肽在超重和肥胖 1 型糖尿病成人患者中的疗效和安全性。
Diabetes Technol Ther. 2024 Jun;26(6):367-374. doi: 10.1089/dia.2024.0050. Epub 2024 Apr 18.
6
Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes.司美格鲁肽在超重和肥胖 1 型糖尿病患者中的疗效。
Diabetes Technol Ther. 2024 Mar;26(3):184-189. doi: 10.1089/dia.2023.0490.
7
Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight.低剂量司美格鲁肽对1型糖尿病超重患者的影响。
Diabetes Res Clin Pract. 2024 Mar;209:111593. doi: 10.1016/j.diabres.2024.111593. Epub 2024 Feb 24.
8
Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.替尔泊肽作为一种治疗肥胖症的新型有效且安全的策略：一项随机对照试验的系统评价和荟萃分析。
Front Public Health. 2024 Jan 31;12:1277113. doi: 10.3389/fpubh.2024.1277113. eCollection 2024.
9
Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study.替尔泊肽治疗1型糖尿病成人患者的疗效和安全性：一项概念验证观察性研究
J Diabetes Sci Technol. 2025 Mar;19(2):292-296. doi: 10.1177/19322968231223991. Epub 2024 Feb 5.
10
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病血糖控制、体重和血脂水平的比较疗效：系统评价和网状Meta分析
BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410.
Zotero 插件